[MAO-(monoamine oxidase-)inhibitor plus lithium. 1. Choice in psychopathologic rapidly changing bipolar manic-depressive patients (rapid cyclers)].
Patients resistant to therapy with lithium or lithium plus tricyclic antidepressants were included in our study. They had shown no curtailment of depression, no lessening of the depth of depression nor any improvement in the manic symptoms. Therapeutic medication with lithium, lithium plus tricyclics, neuroleptics and/or tranquilizer had been tried out for at last three years and the episodes of the manic-depressive illness were documented over this period. The diagnosis in the case of these patients was manic-depressive illness, type bipolar I or II. We report one case covering three years of treatment showing the following trend: Psychopathology did not change after quitting anciliary medication and tricyclic antidepressants while lithium intake was continued. A low-dose MAO inhibitor (tranylcypromine 13.7 mg/die) in addition to lithium led to shortened and less pronounced depressive and manic episodes and more prolonged normorhythmic periods. This trend emerged with even greater clarity during the course of the study.
D001714:Bipolar Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D014191:Tranylcypromine / Q000627:therapeutic use; D014268:Trifluoperazine / Q000627:therapeutic use
D008996:Monoamine Oxidase Inhibitors; D014268:Trifluoperazine; D014191:Tranylcypromine; D008094:Lithium
MAO-(Monoaminoxidase)-Inhibitor plus Lithium. 1. Wahl bei psychopathologisch rasch wechselnden bipolaren manisch-depressiv Erkrankten ("Rapid cyclers").